Adamax
Adamax is a market name without a reproducible public molecular identity. New Zealand regulators grouped the marketed product with ACTH analogues for scheduling, but that classification does not supply a sequence, analytical characterization, mechanism, or clinical evidence.
marketed putative ACTH-analogue peptide
- Market name, not an independently characterized molecule
- Complete sequence and modification state unresolved
- No PubMed paper or registered human trial under the Adamax name
- Classified in New Zealand within prescription ACTH analogues
What exactly is Adamax?
No reproducible public molecular identity has been established for Adamax. Medsafe describes it as a marketed ACTH-analogue product, but independent data do not establish a complete sequence, termini, modifications, molecular mass, reference standard, or peptide map.
- Needed to identify it: complete sequence, termini, modifications, intact mass, peptide mapping, and a qualified reference standard.
- Needed to support mechanism: binding or functional assays on the named test article.
- Needed for injection claims: content, aggregation, sterility, endotoxin, and container-level testing.
Medsafe 2025 · Adamax grouped with ACTH analogues
Government regulatory review
New Zealand Medsafe, submission to the Medicines Classification Committee, June 2025.
Medsafe described Adamax and Semax as marketed cognitive-enhancer peptide products and proposed that ACTH analogues be classified as prescription medicines. The document says mechanisms are often unknown and clinical and long-term safety research is limited. It does not disclose an Adamax sequence or analytical test.
- Study design
- Government market and scheduling review
PubMed · no molecule-specific paper
Literature record set
PubMed records.
PubMed records under the exact Adamax name contained no peptide characterization, mechanism, animal-administration, pharmacokinetic, safety, or efficacy paper. Broader Adamax matches concerned unrelated authors, institutions, or metadata.
- Study design
- Exact-name and peptide-context coverage
Has Adamax been tested in people?
PubMed and ClinicalTrials.gov listed no registered trial or molecule-specific clinical publication for Adamax. Market claims about cognition, mood, neurogenesis, BDNF, or recovery therefore lack a defined test article and human result.
Can Semax evidence be borrowed?
The regulatory document groups two marketed products into a broad ACTH-analogue class. It does not show sequence, dose, or target equivalence, or clinical interchangeability.
Medsafe 2025 · Adamax grouped with ACTH analogues
Government regulatory review
New Zealand Medsafe, submission to the Medicines Classification Committee, June 2025.
Medsafe described Adamax and Semax as marketed cognitive-enhancer peptide products and proposed that ACTH analogues be classified as prescription medicines. The document says mechanisms are often unknown and clinical and long-term safety research is limited. It does not disclose an Adamax sequence or analytical test.
- Study design
- Government market and scheduling review
PubMed · no molecule-specific paper
Literature record set
PubMed records.
PubMed records under the exact Adamax name contained no peptide characterization, mechanism, animal-administration, pharmacokinetic, safety, or efficacy paper. Broader Adamax matches concerned unrelated authors, institutions, or metadata.
- Study design
- Exact-name and peptide-context coverage
ClinicalTrials.gov · no exact intervention trial
Registry record set
ClinicalTrials.gov records.
ClinicalTrials.gov contained no relevant registered human intervention study under the exact Adamax name.
- Study design
- Exact-name and putative-class coverage
Does Adamax have a known mechanism?
The cited records contain no Adamax-specific binding, functional, animal, or pharmacokinetic study. Claims about ACTH receptors, melanocortins, BDNF, or neurogenesis cannot be assigned to Adamax until the molecule is identified and tested.
PubMed · no molecule-specific paper
Literature record set
PubMed records.
PubMed records under the exact Adamax name contained no peptide characterization, mechanism, animal-administration, pharmacokinetic, safety, or efficacy paper. Broader Adamax matches concerned unrelated authors, institutions, or metadata.
- Study design
- Exact-name and peptide-context coverage
Medsafe 2025 · Adamax grouped with ACTH analogues
Government regulatory review
New Zealand Medsafe, submission to the Medicines Classification Committee, June 2025.
Medsafe described Adamax and Semax as marketed cognitive-enhancer peptide products and proposed that ACTH analogues be classified as prescription medicines. The document says mechanisms are often unknown and clinical and long-term safety research is limited. It does not disclose an Adamax sequence or analytical test.
- Study design
- Government market and scheduling review
What is known about safety?
Without a resolved identity or administered-human record, target-mediated, off-target, endocrine, immune, pregnancy, interaction, and dose-related risks cannot be characterized. Product-content and sterile-injection risks are also unresolved.
Evidence from another peptide cannot establish Adamax's safety because Adamax lacks an independently published molecular identity.
PubMed · no molecule-specific paper
Literature record set
PubMed records.
PubMed records under the exact Adamax name contained no peptide characterization, mechanism, animal-administration, pharmacokinetic, safety, or efficacy paper. Broader Adamax matches concerned unrelated authors, institutions, or metadata.
- Study design
- Exact-name and peptide-context coverage
ClinicalTrials.gov · no exact intervention trial
Registry record set
ClinicalTrials.gov records.
ClinicalTrials.gov contained no relevant registered human intervention study under the exact Adamax name.
- Study design
- Exact-name and putative-class coverage
Does New Zealand prescription classification mean Adamax is approved?
New Zealand classified the relevant ACTH-analogue group as prescription medicines to control supply. That classification is not marketing authorization and gives Adamax no approved indication or product-specific authorization.
Medsafe 2025 · Adamax grouped with ACTH analogues
Government regulatory review
New Zealand Medsafe, submission to the Medicines Classification Committee, June 2025.
Medsafe described Adamax and Semax as marketed cognitive-enhancer peptide products and proposed that ACTH analogues be classified as prescription medicines. The document says mechanisms are often unknown and clinical and long-term safety research is limited. It does not disclose an Adamax sequence or analytical test.
- Study design
- Government market and scheduling review
NZ Gazette 2025 · ACTH analogue class
Official legal notice
New Zealand Gazette notice 2025-go7397.
The notice gives legal effect to prescription classification for the relevant ACTH-analogue group in New Zealand. Scheduling controls supply; it does not approve Adamax, validate a clinical indication, or authenticate a product.
- Study design
- Binding New Zealand medicines classification
Studies and sources
Medsafe 2025 · Adamax grouped with ACTH analogues
Government regulatory review
New Zealand Medsafe, submission to the Medicines Classification Committee, June 2025.
Medsafe described Adamax and Semax as marketed cognitive-enhancer peptide products and proposed that ACTH analogues be classified as prescription medicines. The document says mechanisms are often unknown and clinical and long-term safety research is limited. It does not disclose an Adamax sequence or analytical test.
- Study design
- Government market and scheduling review
NZ Gazette 2025 · ACTH analogue class
Official legal notice
New Zealand Gazette notice 2025-go7397.
The notice gives legal effect to prescription classification for the relevant ACTH-analogue group in New Zealand. Scheduling controls supply; it does not approve Adamax, validate a clinical indication, or authenticate a product.
- Study design
- Binding New Zealand medicines classification
PubMed · no molecule-specific paper
Literature record set
PubMed records.
PubMed records under the exact Adamax name contained no peptide characterization, mechanism, animal-administration, pharmacokinetic, safety, or efficacy paper. Broader Adamax matches concerned unrelated authors, institutions, or metadata.
- Study design
- Exact-name and peptide-context coverage
ClinicalTrials.gov · no exact intervention trial
Registry record set
ClinicalTrials.gov records.
ClinicalTrials.gov contained no relevant registered human intervention study under the exact Adamax name.
- Study design
- Exact-name and putative-class coverage
Why is Adamax in D tier?
The D grade reflects an unresolved molecular identity and the absence of independent pharmacology or human studies. New Zealand's regulatory grouping controls supply but does not verify the contents of a vial.